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Abstract
The current pandemic of coronavirus disease 2019 (COV-
ID-19) spotlighted the vulnerability of patients with chronic 
kidney disease stage 5 on maintenance hemodialysis (HD) to 
the viral infection. Social distancing is the most effective pre-
ventive measure to reduce the risk of infection. Nonetheless, 
the necessity to frequently reach the dialysis center and the 
inherent social gathering both impede social distancing and 
also self-quarantine for infected individuals. A baseline hy-
perinflammatory state driven by factors such as the reten-
tion of uremic toxins afflicts these patients. Concomitantly, 
a condition of relative immunosuppression is also attributed 
to similar factors. The use of high-flux (HF) dialyzers for HD is 
the standard of care. However, with HF membranes, the re-
moval of large middle molecules is scant. Medium cutoff 
(MCO) dialyzers are a new class of membranes that allow 
substantial removal of large middle molecules with negligi-
ble albumin losses. Recent trials confirmed long-term safety 
and long-term sustained reduction in the concentration of 
large uremic toxins with MCO dialyzers. Herein, we discuss 
the rationale for applying MCO membranes in COVID-19 pa-
tients and its possible immunoadjuvant effects that could 
mitigate the burden of COVID-19 infection in dialysis pa-
tients. We also discuss the direct cytopathic effect of the vi-
rus on renal tissue and extracorporeal blood purification 
techniques that can prevent kidney damage or reduce acute 
kidney injury progression. © 2020 S. Karger AG, Basel
COVID-19 Pandemic and the Kidney
Since the new COVID-19 outbreak has been declared 
a pandemic, interesting epidemiological and pathophysi-
ological data are emerging [1, 2]. In particular, the preva-
lence of kidney involvement among infected patients is 
difficult to establish due to differences in swab test poli-
cies. Nevertheless, a common scenario takes place with 
two main aspects related to the COVID-19 infection. The 
first is the direct acute kidney injury (AKI) occurring in 
patients admitted to the intensive care unit (ICU). Ap-
proximately 14% of individuals hospitalized for symp-
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tomatic COVID-19 infection require ICU admission [3] 
and 37% develop different stages of AKI. Of those with 
AKI, 14% required renal replacement therapy, meaning 
that 5% of all patients hospitalized with COVID-19 re-
quired some form of dialysis support [4]. In a prospective 
cohort study, 44% of COVID-19 hospitalized patients 
presented proteinuria and 27% hematuria [5]. The sec-
ond aspect relates to chronic kidney disease (CKD) pa-
tients who might develop worsening of renal function or 
are already on some form of chronic dialysis treatment 
[6–11].
Pathophysiology of Kidney Involvement
After the lungs, the kidneys seem to be the most af-
flicted solid organ. SARS-CoV-2 viral load was found in 
all kidney compartments, mainly in glomerular cells 
[12]. Histopathological postmortem findings in 26 pa-
tients showed acute tubular necrosis as the most preva-
lent finding in COVID-19 patients [5], this was corrobo-
rated in a case series from ten patients with AKI that un-
derwent native kidney needle biopsy [13]. Other case 
reports demonstrated viral copies in the cytoplasm of tu-
bular cells [14]. In some infected individuals, the proxi-
mal tubule increases the expression of angiotensin-con-
verting enzyme 2 (ACE2). The enzyme is present in high 
concentrations in the brush border of epithelial cells of 
the tubules. ACE2 acts as a receptor for SARS-CoV-2 
spike protein, through which the virus gains access to the 
host cell [14]. Of note, ACE2 is also present in podocytes 
[15]. Additionally, viral particles were visualized by elec-
tron microscopy in podocytes [15, 16] and glomerular 
endothelial cells [17]. Proteinuria is not among the crite-
ria for diagnosis of AKI according to current definitions 
[18]. Notwithstanding, proteinuria per se is a marker of 
kidney damage. The ubiquitous presence of the virus 
with the invasion of glomerular endothelial cells, podo-
cytes, and tubular cells could explain the high prevalence 
of proteinuria. Damaged endothelial cells and disruption 
of the podocyte network both increase glomerular pro-
tein leakage, overwhelming the proximal tubules’ capac-
ity of protein reabsorption. Moreover, infected tubular 
cells might also be dysfunctional. We hypothesize that if 
biomarkers of tubular injury, such as neutrophil gelatin-
ase-associated lipocalin (NGAL), and of cell-cycle arrest 
such as tissue inhibitor of metalloproteinase-2 (TIMP- 
2) and insulin-like growth factor-binding protein 7 
(IGFBP7) [18] were incorporated into clinical practice, 
the prevalence of AKI, considering also subclinical AKI, 
would sharply increase in COVID-19 patients. Our 
group published the first study evaluating the product 
[TIMP-2]•[IGFBP7] in 23 hospitalized patients with 
SARS-CoV-2 infection. In this ongoing observational 
study there were no clear differences between trends in 
[TIMP-2]•[IGFBP7] of AKI versus non-AKI at admis-
sion. However, all patients that progressed to stage 3 AKI 
had [TIMP-2]•[IGFBP7] levels >2 (ng/mL)2/1,000, and 
all AKI patients with [TIMP-2]•[IGFBP7] levels ≤0.3 
(ng/mL)2/1,000 did not experience progression of their 
AKI stage [19]. We are currently analyzing our data on 
the evaluation of urinary NGAL, a biomarker of tubular 
cell injury.
The ICU patient might also develop AKI as a final 
common pathway of systemic inflammation with aug-
mented immune response leading to unrestrained circu-
lating levels of pro-inflammatory mediators and direct 
cytokine-induced organ damage [20–24]. In general, pa-
tients display a hyperinflammatory state that should be 
considered as a target for different therapeutic options, 
including pharmacological [21–24] and extracorporeal 
[2, 25] cytokine blockade.
Ambulatory care patients with advanced CKD and/or 
undergoing chronic hemodialysis (HD) or peritoneal di-
alysis have 2 different pathways.
1. Some require ICU admission and need prolonged in-
termittent HD or continuous renal replacement ther-
apy (CRRT).
2. Others need to continue their chronic dialysis regimen 
with specific isolation and possibly modified prescrip-
tion based on metabolic and clinical demand [6–11].
Extracorporeal Techniques for COVID-19 Kidney 
Patients
Different approaches should be proposed for different 
indications and different patients. Patients with a system-
ic inflammatory syndrome, hemodynamic instability, 
need for vasopressors, and high serum concentrations of 
cytokines may represent an indication for hemoadsorp-
tion treatment with specific sorbents for few hours in the 
immediate phase and the subsequent use of CRRT to sus-
tain removal of fluid, metabolites, and inflammatory me-
diators for hours or days [2, 25]. In a recent case report, 
Berlot et al. [26] applied both tocilizumab, an interleukin 
(IL)-6 antagonist, and hemoperfusion with a neutro-
macroporous sorbent cartridge in a severely ill patient 
with COVID-19 pneumonia and acute respiratory dis-
tress syndrome. The patient had clinical and laboratory 
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signs of a hyperinflammatory state, and after hemoperfu-
sion therapy (1 session per day in 3 consecutive days), 
there was a marked improvement in the respiratory index 
and chest radiography, along with reductions in IL-6 and 
C-reactive protein. The patient was extubated after 5 days 
and survived hospitalization. Of note, this patient was not 
on renal replacement therapy, illustrating that extracor-
poreal blood purification techniques can be applied even 
in the absence of kidney injury to prevent organ damage 
and mitigate organ failure. Other extracorporeal blood 
purification techniques that can be used in COVID-19 
patients to remove inflammatory molecules are as fol-
lows:
1. Therapeutic plasma exchange.
2. Adsorptive cartridges containing polystyrene fibers 
functionalized with polymyxin-B, aiming endotoxin 
removal in patients with superimposed Gram-nega-
tive sepsis.
3. Adsorptive CRRT membranes such as acrylonitrile 
and sodium methallyl sulfonate plus polyethylenimine 
(AN69-PEI); surface-treated AN69; or polymethyl 
methacrylate.
4. Medium cutoff (MCO) or high cutoff HD membranes 
which can remove inflammatory mediators by means 
of diffusion and convection [25].
In patients with stage 5 CKD on maintenance HD 
treatment, extra removal of pro-inflammatory mediators 
may also represent a logical approach.
Rationale for MCO Membrane Application in Chronic 
HD Patients
Recent reports have elucidated the removal mecha-
nism of large middle molecular weight solutes including 
cytokines with the application of MCO membranes. In 
particular, this has been studied in chronic treatments de-
fined as expanded HD [27]. MCO membranes present a 
significantly improved sieving curve compared to high-
flux (HF) membranes and a high retention onset value. 
At the same time, they display a significantly lower albu-
min loss than high cutoff membranes, allowing for safe 
and long-term applications [28]. These characteristics 
represent a phenomenal compromise to obtain the de-
sired therapeutic target in COVID-19 patients both for 
chronic dialysis continuation and for application in 
CRRT. Although MCO dialyzers have not been indicated 
for CRRT in acute patients, we have personally tested the 
safe application with negligible albumin loss and im-
proved cytokine clearance.
Clinical Experience with MCO Membrane
The retention of a large number of solutes that are nor-
mally excreted or metabolized by the kidney is responsi-
ble for the classical symptoms in HD patients. These mol-
ecules are defined as uremic toxins and can be classified 
into 3 groups: small water-soluble molecules, middle 
molecules, and protein-bound toxins. The MCO dialyzer 
allows the removal of middle molecules up to approxi-
mately 50,000 Da [29, 30].
We performed a prospective, open-label, controlled, 
cross-over study comparing the MCO dialyzer versus HF 
dialyzer in 20 patients [31]. Initially, 10 patients under-
went conventional HF-HD and 10 patients underwent 
conventional MCO-HD for 3 months. Later, the patients 
switched and received the other treatment for a further 3 
months. We demonstrated decreases in the levels of IL-1β 
and IL-6 among patients receiving MCO-HD compared 
to those receiving conventional HF-HD. We also found a 
reduction in the incidence of infections during the MCO-
HD phase. Although difficult to interpret, because of the 
small sample size and potential bias, this result is very en-
couraging since infectious diseases are highly common in 
HD patients. These patients are more prone to infections 
with worse outcomes than the general population, mainly 
because of the high prevalence of diabetes mellitus, the 
presence of an indwelling catheter, and a condition of ac-
quired immune dysfunction due to the retention of ure-
mic toxins and chronic inflammation [32]. In accordance, 
a retrospective analysis comparing 49 chronic dialytic pa-
tients hospitalized with COVID-19 pneumonia versus 52 
non-CKD patients hospitalized with COVID-19 pneumo-
nia showed that chronic HD patients had lower lympho-
cyte counts, more abnormalities seen in chest computed 
tomography, higher incidence of shock, acute respiratory 
distress syndrome, and higher mortality risk [33].
We can propose different pathways through which 
MCO-HD could play a role in reducing the rate of severe 
infections. One of these is that treatment with MCO 
membranes may reduce inflammation, as supported by 
the lowering of the concentration of inflammatory cyto-
kines and the reduction of transcription of pro-inflam-
matory cytokines in peripheral leukocytes [34]. Another 
possible explanation for the decrease of infectious events 
could be that MCO-HD reduces serum concentration of 
free light chains (FLC) since their retention in CKD pa-
tients is associated with in vitro inhibition of leukocyte 
chemotaxis [29].
Uniformly with our findings, two other recent trials de-
monstrated a reduction in the concentration of FLC [28, 
Ronco/Reis/CozzolinoNephron4
DOI: 10.1159/000509807
35]. One of the studies was similar in design to ours: a ran-
domized, open-label, cross-over study, with 40 patients 
who were divided to carry out 3 months of MCO-HD fol-
lowed by 3 months of HF-HD, or vice versa [35]. The pri-
mary outcome was myoglobin (17 kDa) reduction rate 
(RR) after 3 months of MCO-HD compared to HF-HD. 
The RR for any given solute equals the subtraction of the 
pre-session from the post-session concentration, divided 
by the pre-session concentration. A statistically signifi-
cant increase in myoglobin RR was found during the 
MCO dialyzer intervention period. However, the pre-di-
alysis concentration of myoglobin was similar in both 
groups, probably due to a rebound effect and redistribu-
tion of myoglobin into the blood compartment. Second-
ary outcomes included RR and pre-dialysis serum concen-
tration of other middle molecules such as β2-microglobulin 
(11.8 kDa), tumor necrosis factor-alpha (17.2 kDa), IL-6 
(21 kDa), kappa FLC (22 kDa), prolactin (23 kDa), and 
lambda FLC (45 kDa). Importantly, not only was the RR 
of β2-microglobulin and FLC higher with the MCO dia-
lyzer, but the pre-dialysis serum concentrations of β2-
microglobulin and FLC were also lower during the MCO-
HD phase, demonstrating that the effects of higher re-
moval of middle molecules were sustained until the next 
dialytic treatment. The extrapolation of these results to 
cytokine removal based on their molecular weight is too 
simplistic. Accordingly, there was no difference in RR and 
pre-dialysis serum concentration for tumor necrosis fac-
tor-alpha (17.2 kDa) and IL-6 (21 kDa), irrespective of the 
dialytic membrane utilized. The virtual molecular radius, 
electrical charges, and protein binding are other variables 
that impact on solute clearance [36].
The other study, REMOVAL-HD [28], was a multi-
center, open-label, non-randomized, single-arm trial 
with 89 individuals assigned to receive 4 weeks of HF-HD 
as wash-in, then 24 weeks of MCO-HD, and finally 4 
weeks of HF-HD as wash-out. The primary endpoint was 
change in pre-dialysis serum albumin concentration be-
fore and after 6 months of MCO-HD. There was no dif-
ference in albumin concentration during the trial visits. 
After 2 weeks on MCO-HD, pre-dialysis serum concen-
trations of FLC were reduced, and this effect was main-
tained during the following 22 weeks of application of 
MCO membrane. The return to baseline values occurred 
2 weeks after the return to HF-HD. These results cannot 
be generalized to all HD patients since malnourished pa-
tients and those with poor vascular access (blood flow 
<300 mL/min) were ineligible for the study.
As an innovative treatment, the efficacy and safety of 
MCO-HD should be proven. The primary concern about 
safety mainly related to albumin losses has been over-
come. Higher removal of middle molecules has been con-
sistently seen in recent trials [28, 31, 35]. The application 
of MCO membranes in patients currently undergoing 
HF-HD could potentially reduce the incidence of infec-
tions. Moreover, in the COVID-19 outbreak, the higher 
clearance of FLC and some inflammatory cytokines may 
reduce the progression of mild presentations to moderate 
or severe clinical pictures in HD patients with COVID-19.
Conclusion
Our understanding of kidney involvement in COV-
ID-19 has changed substantially in the past months. The 
renal tropism of SARS-CoV-2 is frequent [12]. The direct 
kidney invasion, as well as a hyperinflammatory state, 
might cause kidney damage [1, 2]. Extracorporeal tech-
niques can be helpful in the modulation of an immune 
dysregulated response, both in the severely ill and in the 
chronic HD patient. Recent clinical trials demonstrated 
consistent results regarding the application of MCO 
membranes in patients on maintenance HD [28, 31, 35]. 
These trials confirmed long-term safety and long-term 
sustained reductions in the concentrations of large ure-
mic toxins, cytokines, and FLC with MCO-HD when 
compared to conventional HF-HD. In the context of the 
COVID-19 pandemic, we presented the rationale that 
supports the use of MCO dialyzers in the chronic dialysis 
regimen. This strategy has been used in many dialysis fa-
cilities across Italy with the scope to prevent severe pre-
sentations of COVID-19. We aim to share our insights 
with the nephrology community and foster future col-
laborations between centers that will be fruitful to create 
new scientific evidence.
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